Skip to main content
Premium Trial:

Request an Annual Quote

Cell Biosciences Completes Alpha Innotech Buy

NEW YORK (GenomeWeb News) – Cell Biosciences on Wednesday said that it had completed the acquisition of Alpha Innotech.

Santa Clara, Calif.-based Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

The firms announced the deal in early September.

Alpha Innotech is based in San Leandro, Calif., and had 2008 revenues of $17.6 million. The firm sells digital imaging systems used for genomic and proteomic research, and has sold more than 10,000 of its systems worldwide. Its products complement Cell Biosciences' CB1000 system, a nanofluidic immunoassay platform for detecting and characterizing oncoproteins and other signaling proteins in ultra-small biological samples.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.